RECRUITING Phase 1 / Phase 2 ClinicalTrials.gov

FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS

Sponsor: Trace Neuroscience, Inc. • ClinicalTrials.gov ID: NCT07674667

Registry updated: 2026-10-14

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The FUNCtion Amyotrophic Lateral Sclerosis (ALS) trial is a randomized, double-blind, placebo-controlled Phase 1/2 trial to evaluate the safety and tolerability of TRCN-1023 in adults living with ALS. TRCN-1023 is an investigational medicine given as a single injection into the fluid surrounding the spine (intrathecal injection). The trial will also assess how the body processes the drug and whether it shows early signs of benefit over 24 weeks.

Interventions

TRCN-1023 (Drug)
TRCN-1023 administered as an intrathecal injection.
Placebo (Other)
Intrathecal injection of artificial cerebrospinal fluid (aCSF).

Eligibility criteria

Key Inclusion Criteria: * Adults aged 18 to 75 years * Diagnosis of ALS (clinically definite, clinically probable, or clinically probable laboratory supported) * ALS symptoms began within the past 24 months * Able to perform breathing tests: slow vital capacity (SVC) with consistent results, with breathing capacity of at least 60% of the expected value * Able and willing to meet all study requirements, including travel to the study site, brain magnetic resonance imaging (MRI) scans, lumbar punctures, and blood draws * Able and willing to use wearable sensors and complete speech assessments at home * On a stable dose of approved ALS medication for at least 4 weeks prior to screening * Capable of providing informed consent Key Exclusion Criteria: * Carries a confirmed SOD1 or FUS gene mutation * Has a tracheostomy or requires continuous assisted ventilation more than 22 hours per day during the preceding 3 months before the first Screening Visit * Has a contraindication to brain MRI (e.g., pacemaker, metal implants) * Has a contraindication to lumbar puncture or spinal injection (e.g., blood clotting disorders, certain blood thinners, signs of increased pressure in the brain) * Has significant abnormal liver, kidney, or blood test results * Is currently enrolled in another clinical trial or has received an investigational treatment within the past 4 weeks * Has previously received gene therapy, stem cell therapy, or another Antisense oligonucleotide (ASO) treatment * Has a clinically significant condition other than ALS that could interfere with study participation

Conditions

Amyotrophic Lateral Sclerosis

Locations

Universitätsklinikum Schleswig-Holstein — Lübeck, Schleswig-Holstein, Germany
TUM Klinikum Rechts der Isar — Munich, Germany
University Medical Center Rostock — Rostock, Germany
University Medical Center Utrecht — Utrecht, Netherlands
University College London — London, United Kingdom
University of Sheffield — Sheffield, United Kingdom

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment